These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11552901)

  • 1. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study.
    Reinisch W; Nahavandi H; Santella R; Zhang Y; Gasché C; Moser G; Waldhör T; Gangl A; Vogelsang H; Knobler R
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1313-22. PubMed ID: 11552901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial.
    Reinisch W; Knobler R; Rutgeerts PJ; Ochsenkühn T; Anderson F; von Tirpitz C; Kaatz M; Janneke van der Woude C; Parenti D; Mannon PJ
    Inflamm Bowel Dis; 2013 Feb; 19(2):293-300. PubMed ID: 22573600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal photochemotherapy for the treatment of refractory Crohn's disease.
    Bisaccia E; Palangio M; Gonzalez J
    Transfus Apher Sci; 2007 Oct; 37(2):171-4. PubMed ID: 17993292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
    Abreu MT; von Tirpitz C; Hardi R; Kaatz M; Van Assche G; Rutgeerts P; Bisaccia E; Goerdt S; Hanauer S; Knobler R; Mannon P; Mayer L; Ochsenkuhn T; Sandborn WJ; Parenti D; Lee K; Reinisch W;
    Inflamm Bowel Dis; 2009 Jun; 15(6):829-36. PubMed ID: 19130617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn's Disease.
    Cheerva A; Dillard R; Bertolone S
    J Clin Apher; 2013 Oct; 28(5):381-6. PubMed ID: 23720057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid dependency in Crohn's disease.
    Reinisch W; Vogelsang H
    Gastroenterology; 2002 Jul; 123(1):393-5; author reply 395. PubMed ID: 12105883
    [No Abstract]   [Full Text] [Related]  

  • 8. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.
    Landi B; Anh TN; Cortot A; Soule JC; Rene E; Gendre JP; Bories P; See A; Metman EH; Florent C
    Gastroenterology; 1992 May; 102(5):1647-53. PubMed ID: 1568574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease.
    Zoli G; Carè M; Parazza M; Spanò C; Biagi PL; Bernardi M; Gasbarrini G
    Aliment Pharmacol Ther; 1997 Aug; 11(4):735-40. PubMed ID: 9305483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
    Selby W; Pavli P; Crotty B; Florin T; Radford-Smith G; Gibson P; Mitchell B; Connell W; Read R; Merrett M; Ee H; Hetzel D;
    Gastroenterology; 2007 Jun; 132(7):2313-9. PubMed ID: 17570206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure.
    Gunduz M; Atilla E; Atilla PA; Topcuoglu P; Ilhan O
    Transfus Clin Biol; 2019 Feb; 26(1):32-37. PubMed ID: 29655590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
    Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
    Andus T; Gross V; Caesar I; Schulz HJ; Lochs H; Strohm WD; Gierend M; Weber A; Ewe K; Schölmerich J;
    Dig Dis Sci; 2003 Feb; 48(2):373-8. PubMed ID: 12643618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.
    Orlando A; Renna S; Mocciaro F; Cappello M; Di Mitri R; Randazzo C; Cottone M
    Inflamm Bowel Dis; 2012 May; 18(5):826-31. PubMed ID: 21837774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
    Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J
    Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis for the treatment of Crohn's disease.
    Fowler S; Jones J; Hull PR; Ghosh S
    Transfus Apher Sci; 2015 Apr; 52(2):183-6. PubMed ID: 25747960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.